Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I b/ II Clinical Study of Iribrine Mesylate Plus Tucidinostat in the Treatment of HR+/HER2- Locally Relapsed or Metastatic Breast Cancer After Previous CDK4/6 Inhibitor Failure

NCT05335473 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT05335473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05335473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I b/ II Clinical Study of Iribrine Mesylate Plus Tucidinostat in the Treatment of HR+/HER2- Locally Relapsed or Metastatic Breast Cancer After Previous CDK4/6 Inhibitor Failure
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 13, 2022
Completion date
November 1, 2025
Enrollment
87 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hr positive her2 negative advanced breast cancer